Catalyst Brief

← Calendar

ReadoutIn window

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. — A166

Phase 3 primary completion: A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy.

Date
Nov 2026
Type
Readout
Indication
HER2-positive Breast Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

  1. May2027
  2. Dec2026